hackint0sh/New-Dataset huggingface dataset:
2. Analyze and study the reasons and factors that affect the physical and mental impact of effective family companionship on patients with advanced breast cancer Participants will be divided into a companion group and a non-accompaniment group. Patients in the companion group are given graded companion intervention methods. A comparison group: Researchers will compare a non-accompaniment group to see if the physical and mental impact of companionship on patients. conditions: Breast Cancer studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: OTHER masking: NONE count: 304 type: ESTIMATED name: Graded companionship measure: Change from Baseline meatal state on GAD-7 at Week 48. measure: Change from Baseline physical state on kps at Week 48. sex: FEMALE minimumAge: 21 Years maximumAge: 72 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology status: RECRUITING city: Wuhan zip: 430022 country: China name: Peng Xin, postgraduate role: CONTACT lat: 30.58333 lon: 114.26667 hasResults: False
nctId: NCT06385652 id: PekingUFH-MM-NB381 briefTitle: PET Imaging Study of 68Ga-NB381 in Multiple Myeloma overallStatus: RECRUITING date: 2024-04-01 date: 2025-04-01 date: 2026-12-31 date: 2024-04-26 date: 2024-04-26 name: Peking University First Hospital class: OTHER briefSummary: Multiple myeloma (MM) predominantly affects the elderly, often presenting insidiously and with a rising incidence rate. Current diagnostic methods primarily rely on invasive bone marrow biopsies, which can lead to false-negative results if the biopsy site is improperly chosen. CD38 is significantly overexpressed on the surface of malignant plasma cells in MM, making it a characteristic tumor biomarker for this disease.
Addressing the limitations in specificity and sensitivity of traditional PET imaging agents, this project is dedicated to developing a new type of nanobody PET/CT imaging probe, 68Ga-NB381, which possesses high affinity and targets CD38. This probe, which is an intellectual property of our institution, aims to enhance the accuracy and specificity of early MM diagnosis. In terms of clinical evaluation, the project will implement a comprehensive assessment process including case selection, collection of baseline information, high-precision imaging, expert-level image interpretation, and follow-up studies, comparing directly with traditional 18F-FDG imaging to thoroughly verify the specificity and safety of 68Ga-NB381. This lays the groundwork for the clinical translation of this radiopharmaceutical in China. Furthermore, the project contributes to formulating more effective precision treatment plans based on CD38 expression levels and provides evidence for monitoring the therapeutic effects of daratumumab, a drug also targeting CD38. This makes the project of significant academic value and clinical importance, thus promoting the development of personalized treatment strategies. conditions: Multiple Myeloma studyType: INTERVENTIONAL phases: EARLY_PHASE1 allocation: NA interventionModel: SEQUENTIAL interventionModelDescription: In this sequential assignment clinical trial, we aim to evaluate and compare the diagnostic performance of two PET imaging agents, 68Ga-NB381 and 18F-FDG, in patients diagnosed with multiple myeloma (MM). The study will enroll MM patients who meet the inclusion criteria and are scheduled for routine diagnostic imaging.
Each participant will undergo PET imaging with 18F-FDG first, followed by a second PET scan using 68Ga-NB381 (or reversed). To minimize potential interference between the two imaging sessions and ensure patient safety, a minimum interval of one day will be maintained between the two scans, with all imaging completed within one week. This sequential imaging approach allows for direct comparison of the imaging agents in the same patient, thus controlling for inter-patient variability and providing a more accurate assessment of the relative merits of each imaging agent in the same metabolic and pathological condition. primaryPurpose: DIAGNOSTIC masking: NONE maskingDescription: All PET/CT images are jointly interpreted by at least two imaging and nuclear medicine physicians, each with several years of diagnostic experience and at least at the attending physician level. They compare and record the number of lesions detected and the SUVs (Standard Uptake Values) for both 18F-FDG and 68Ga-NB381 PET/CT scans. After consultation, they provide a unified diagnostic opinion. count: 30 type: ESTIMATED name: 68Ga-NB381 measure: Specificity and Binding Efficiency of 68Ga-NB381 in CD38 Positive Tumors sex: ALL minimumAge: 18 Years maximumAge: 80 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Peking University First Hospital status: RECRUITING city: Beijing state: Beijing zip: 100000 country: China name: Ronghui Yu, Master role: CONTACT phone: +8613466379791 email: kyc@bjmu.edu.cn name: Lei Kang, MD role: PRINCIPAL_INVESTIGATOR name: TIANYAO Wang, PhD role: PRINCIPAL_INVESTIGATOR name: Yongkang Qiu, Master role: SUB_INVESTIGATOR name: Zhenghao Tong, MD role: SUB_INVESTIGATOR lat: 39.9075 lon: 116.39723 hasResults: False
nctId: NCT06385639 id: WK2024005 briefTitle: Efficacy and Safety of Probiotic Products for Digestive Health overallStatus: RECRUITING date: 2024-04-25 date: 2024-05-25 date: 2024-06-25 date: 2024-04-26 date: 2024-04-26 name: Wecare Probiotics Co., Ltd. class: INDUSTRY briefSummary: The objective of this study is to evaluate the efficacy and safety of the probiotic product as an everyday gut health product in supporting digestive environment and homeostasis of gut microbiota. conditions: Healthy Adult studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: PREVENTION masking: SINGLE whoMasked: PARTICIPANT count: 60 type: ESTIMATED name: Probiotic measure: Intestinal health sex: ALL minimumAge: 18 Years maximumAge: 60 Years stdAges: ADULT facility: Danang@Equilab-Int.Com status: RECRUITING city: Jakarta state: Pusat zip: 10430 country: Indonesia name: Danang A. Yunaidi, MD role: CONTACT phone: 217515932 phoneExt: +62 email: danang@equilab-int.com lat: -6.21462 lon: 106.84513 hasResults: False
nctId: NCT06385626 id: UREC: 23_15-Raspberry Leaf Tea briefTitle: The Effects of Raspberry Leaf Tea on Blood Glucose Control acronym: RLT overallStatus: RECRUITING date: 2023-12-18 date: 2024-12-23 date: 2024-12-23 date: 2024-04-26 date: 2024-04-26 name: University of Reading class: OTHER briefSummary: The aim of the present clinical trial is to assess how raspberry leaf polyphenols impact on postprandial glucose and insulin levels in healthy individuals consuming sucrose.
20 healthy adults will be recruited between the ages of 18-65 years who are non-smokers and not taking certain types of medication (e.g., drugs from a GP for high blood pressure, high blood fats, inflammatory conditions, and depression) or dietary supplements (e.g., cholesterol-lowering spreads, fish oil, probiotics, prebiotics, and natural laxatives), antibiotics in the last three months or if they used any drugs or supplements that could affect their blood glucose or lipid metabolism. No abnormal results for liver function tests, renal function tests, and lipid profile tests. If they have food allergies or consume more than 14 units of alcohol per week (i.e., to help they calculate a alcohol intake, one standard glass of wine (175 ml) or one pint of regular lager is equivalent to just over two units of alcohol), frequently travel for work or are participating in another intervention study, they will not be able to participate. Women who are pregnant or lactating or planning a pregnancy in the next six months will also not be able to take part, not use herbal medicines for at least the previous three months, not be on a weight loss program six months before screening, not involved in clinical trials six months before the screening, and not having severe cardiac, hepatic, or renal function impairment. Not Sufferers of chronic illnesses, not Individuals with food allergies, not people with coeliac disease.
They will be asked to attend a four-study visit after an eight-hour overnight fast. Volunteers will be asked to consume 50 g of carbohydrate powder (sucrose and glucose) with or without 10 g of raspberry leaf tea, which will be dissolved in 300 mL of warm water during four visits (every month). Blood samples will be taken at intervals for a period of two hours after the consumption of raspberry leaf or control. Blood glucose and insulin levels will be tested 15 minutes before, at 15,30,60,90, and 120 minutes after carbohydrate intake. conditions: Type II Diabetes studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: CROSSOVER interventionModelDescription: Volunteers will be asked to consume 50 g of carbohydrate powder (sucrose and glucose) with or without 10 g of raspberry leaf tea, which will be dissolved in 300 mL of warm water during four visits (every month). primaryPurpose: PREVENTION masking: NONE count: 20 type: ESTIMATED name: Raspberry leaf tea measure: Blood Glucose sex: ALL minimumAge: 18 Years maximumAge: 65 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Hugh Sinclair Unit of Human Nutrition, University of Reading status: RECRUITING city: Reading state: Berkshire zip: RG6 5SG country: United Kingdom lat: 51.45625 lon: -0.97113 hasResults: False
nctId: NCT06385600 id: severe preeclampsia briefTitle: Intravenous Labetalol vs Phentolamine for the Management of Severe Preeclampsia. overallStatus: NOT_YET_RECRUITING date: 2024-05-20 date: 2026-01-20 date: 2026-03-20 date: 2024-04-26 date: 2024-04-26 name: Assiut University class: OTHER briefSummary: The only effective treatment of severe preeclampsia is delivery of the fetus but immediate antihypertensive treatment is given to stabilize the patient and prevent further complications. All antihypertensive medication can potentially cross the placenta. At this time, there are no randomized control trials to base a recommendation for the use of one antihypertensive agent over another. However, certain medications are effective in lowering blood pressure with an acceptable safety profile in pregnancy. The choice of therapy depends on the acuity and severity of hypertension conditions: Severe Pre-eclampsia studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: DOUBLE whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER count: 200 type: ESTIMATED name: Labetalol name: Phentolamine measure: the effect of Labetalol and Phentolamine on MCA flow velocity by transcranial Doppler monitoring. measure: The effect of labetalol and phentolamine on blood pressure of the patients sex: FEMALE minimumAge: 18 Years maximumAge: 45 Years stdAges: ADULT hasResults: False
nctId: NCT06385587 id: ADH-OL-Study-01-23 briefTitle: Technology-based Symptom Monitoring Intervention for Locally Advanced Head and Neck Cancer Patients acronym: SYMTECH01 overallStatus: NOT_YET_RECRUITING date: 2024-05-03 date: 2024-12-29 date: 2025-09-27 date: 2024-04-26 date: 2024-04-29 name: Aptar Digital Health class: INDUSTRY briefSummary: The goal of this observational study is to assess the satisfaction and usability of an interactive and patient-centered mobile application (app), Oleena™, designed to assist head and neck cancer patients undergoing chemoradiation in managing common and distressing symptoms in real-time, as well as to assess the satisfaction and usability of the related HCP web portal. Additional secondary usage and clinical endpoints that would be used to assess intervention efficacy in future trials will be collected. conditions: Head and Neck Cancer studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 30 type: ESTIMATED name: Oleena measure: Users' satisfaction measure: Feasibility of the technology enabled symptom management solution measure: Usability of the technology enabled symptom management solution measure: Appropriateness of the recommendations measure: Semi-structured exit interviews measure: Symptom burden will be measured using the NIH PRO-CTCAE measurement system, which includes validated scales for individual toxicities measure: Quality of life will be measured using the previously validated FACT-G scale measure: Treatment adherence measure: Health-economic outcome measure: Complaints, alleged deficiencies or malfunctions of the device reported sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06385574 id: 2023-088 briefTitle: Technological Based Rehabilitation on Individuals With Rheumatic Disease overallStatus: RECRUITING date: 2024-03-15 date: 2024-05-15 date: 2024-05-20 date: 2024-04-26 date: 2024-04-26 name: Akdeniz University class: OTHER briefSummary: Affects such as pain, swelling, tenderness, deformities, limitations, strength and function losses, skill and coordination deficiencies in the hand joints, which are frequently seen in rheumatism patients with hand involvement, are included in body structure and function disorders within the framework of International Classification of Function System. Leap Motion Controller is used in hand rehabilitation because it is small in size, low-cost, portable, non-contact, easy to use and provides visual and auditory feedback. The aim of our study is to examine the effect of technology-based rehabilitation on joint range of motion, grip strength, functionality and disease activity in adult individuals with rheumatic disease with hand involvement; and also to compare these effects with the effects of the hand rehabilitation program implemented under the guidance of a physiotherapist and the control group that continues its routine life. conditions: Rheumatic Diseases conditions: Hand Rheumatism conditions: Virtual Reality Therapy studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: There are three groups in the study. First group is leap motion interventional group, second group is hand exercises group and the third group is waiting list. primaryPurpose: TREATMENT masking: DOUBLE maskingDescription: Investigator and outcome assessors do not know which patient is in which group. whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 45 type: ESTIMATED name: Virtual reality therapy measure: Hand grip strength measurement measure: Jebsen Hand Function Test (JHFT) measure: Nine Hole Peg Test (NHPT) measure: Duruoz Hand Index (DHI) measure: Michigan Hand Outcome questionnaire (MHQ) measure: Disease Activity Score 28 (DAS 28) measure: Hand fine grip strength measurement sex: ALL minimumAge: 18 Years maximumAge: 64 Years stdAges: ADULT facility: Sebahat Yaprak Cetin status: RECRUITING city: Antalya state: Konyaaltı zip: 07100 country: Turkey name: Sebahat Yaprak Cetin, PhD role: CONTACT email: fzt.ycetin@gmail.com lat: 36.90812 lon: 30.69556 hasResults: False
nctId: NCT06385561 id: Tramadol_OIBD id: 2022-500108-23-00 type: CTIS briefTitle: The Influence of Tramadol on Opioid-induced Bowel Dysfunction overallStatus: COMPLETED date: 2022-08-11 date: 2023-05-15 date: 2023-05-15 date: 2024-04-26 date: 2024-04-26 name: Asbjørn Mohr Drewes class: OTHER briefSummary: Tramadol is a weak opioid and widely used to treat moderate to severe pain. Stronger opioids are known to inhibit gastrointestinal motility and secretion, however the effects of tramadol on gastrointestinal function remains less understood. The aim of this study was to determine to what degree tramadol causes opioid-induced bowel dysfunction by using an objective design to explore gastrointestinal transit, motility pattern, secretion, and colonic volume, in a group of healthy male volunteers. conditions: Opioid-Induced Bowel Dysfunction conditions: Constipation studyType: INTERVENTIONAL phases: PHASE2 allocation: RANDOMIZED interventionModel: CROSSOVER primaryPurpose: TREATMENT masking: TRIPLE whoMasked: PARTICIPANT whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 20 type: ACTUAL name: Tramadol name: Placebo measure: Total gastrointestinal transit time measure: Colorectal transit time measure: Constipation symptoms measure: Bowel movement frequency measure: Stool consistency measure: Gastrointestinal symptoms measure: Opioid-induced constipation measure: Diagnostic evaluation of opioid-induced constipation measure: Colonic motility patterns measure: Opiate withdrawal symptoms measure: Colon volume measure: Colonic water content measure: Gastric half emptying time measure: Gastric contraction assessment measure: Gastric contraction assessment measure: Small bowel motility assessment measure: Small bowel water content sex: MALE minimumAge: 20 Years maximumAge: 40 Years stdAges: ADULT facility: Aalborg University Hospital city: Aalborg zip: 9000 country: Denmark lat: 57.048 lon: 9.9187 hasResults: False
nctId: NCT06385548 id: VHIO21001 briefTitle: Efficacy and Safety Study of Lurbinectedin and Dostarlimab in Cancer Patients: Protocol VHIO21001 - LiDer acronym: LiDer overallStatus: NOT_YET_RECRUITING date: 2024-04 date: 2024-04 date: 2026-04 date: 2024-04-26 date: 2024-04-26 name: Vall d'Hebron Institute of Oncology class: OTHER briefSummary: Background:
Endometrial cancer is a prevalent gynecological malignancy, with a significant number of cases diagnosed at an advanced stage or recurring following initial treatment. Platinum-based chemotherapy represents a standard treatment option for these patients; however, disease progression often occurs, highlighting the need for novel therapeutic approaches. Lurbinectedin, a synthetic analog of marine alkaloid-derived compounds, and dostarlimab, a monoclonal antibody targeting PD-1, have demonstrated promising antitumor activity in various malignancies. This phase I-II clinical trial seeks to evaluate the safety, tolerability, and efficacy of combining lurbinectedin and dostarlimab in patients with advanced or recurrent endometrial cancer who have experienced disease progression following platinum-based chemotherapy.
To investigate the impact of lurbinectedin and dostarlimab combination therapy on quality of life and symptom control in patients with advanced or recurrent endometrial cancer. conditions: Endometrial Cancer studyType: INTERVENTIONAL phases: PHASE1 phases: PHASE2 allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 15 type: ESTIMATED name: Lurbinectedin name: Dostarlimab measure: Maximum Tolerated Dose (MTD) and Recommended Dose (RD) Determination measure: Evaluation of Lurbinectedin and Dostarlimab Combination Therapy in Advanced/Recurrent Cervical Cancer Patients measure: Safety Evaluation of Lurbinectedin in combination with Dostarlimab measure: Evaluate the progression-free survival (PFS) measure: Pharmacokinetic (PK) and Pharmacogenomic Evaluation measure: Overall Response Rate (ORR) measure: Evaluate the Duration of Response (DOR) measure: Evaluate the Clinical Benefit Rate (CBR) sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06385535 id: IRB_00171031 briefTitle: Clinical Characteristics and Temporal Properties of Individual Tics in Persistent Tic Disorder acronym: PTD overallStatus: RECRUITING date: 2024-04-04 date: 2024-12 date: 2024-12 date: 2024-04-26 date: 2024-04-26 name: University of Utah class: OTHER briefSummary: The goal of this clinical study is to learn more about the timing of tics (sudden, fast movements and sounds that people do and make without meaning to) in people who have multiple tics that have been going on for more than one year. The main questions it aims to answer are:
nctId: NCT06385522 id: BITR2101-C-01 briefTitle: A Clinical Trial in Adults With Non-Hodgkin Lymphoma (NHL), With a Particular Emphasis on Cutaneous T Cell Lymphoma (CTCL), Testing the Safety and Activity of a Novel Drug to Inhibit a Protein Called Tumor Necrosis Factor Receptor 2 That Drives Both Lymphoma Growth and Escape of the Immune System overallStatus: NOT_YET_RECRUITING date: 2024-08 date: 2027-02 date: 2027-02 date: 2024-04-26 date: 2024-04-26 name: Boston Immune Technologies and Therapeutics class: INDUSTRY briefSummary: The goal of this trial is to learn if a new drug, BITR2101, works to treat non-Hodgkin lymphoma (NHL) in adults, with CTCL patients being sought in particular. The trial also seeks to learn about the safety of this drug. This drug is a protein called an antibody. The drug prevents a molecule called a receptor, named TNFR2, from being made. TNFR2 regulates the immune system and provides important signals to lymphoma cells to grow, make more of themselves and survive. When the drug prevents TNFR2 from being produced in lymphoma cells from CTCL patients, those cells died in the laboratory. Therefore, the trial seeks to enroll CTCL patients in particular, in addition to other subtypes of NHL. When the drug prevents the receptor from being made in certain immune cells, there is increased immune activity. Thus, the trial will test if this drug is a new immune therapy that helps the immune system to keep lymphoma under control. In particular, we want to find out if the amount of lymphoma in the body decreases while taking the drug. Patients with autoimmune diseases are not permitted because of this potential increase in immunity brought on by this drug. Patients should have NHL that has been previously treated, that is getting worse on their current therapy, and their doctors think a new treatment is needed. All patients will receive BITR2101 by a 3 hour infusion into a vein, periodically, initially every 3 weeks. There is no placebo in this trial. Visits to the clinic facility will be required, initially at least every week and later less frequently. Patients will be expected to report changes in their health to the clinic staff including new findings and any change in the status of their lymphoma they may be aware of. Patients can continue to receive BITR2101 for up to a year or until their lymphoma worsens. For patients who are clearly benefiting, they may be able to receive BITR2101 for another year. conditions: NHL conditions: Cutaneous T Cell Lymphoma conditions: Peripheral T-cell Lymphoma studyType: INTERVENTIONAL phases: PHASE1 allocation: NA interventionModel: SEQUENTIAL primaryPurpose: TREATMENT masking: NONE count: 37 type: ESTIMATED name: BITR2101 measure: to assess the safety and tolerability of BITR2101 administered intravenously every 3 weeks in order to determine the MTD, if any, and to inform the RDE sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06385509 id: TOL-CLAR-20024 briefTitle: A Phase 4 Study to Evaluate Adrenal Function in Hypogonadal Men Treated With JATENZO® for 12 Months overallStatus: NOT_YET_RECRUITING date: 2024-04 date: 2025-10 date: 2026-02 date: 2024-04-26 date: 2024-04-26 name: Tolmar Inc. class: INDUSTRY name: ICON plc briefSummary: TOL-CLAR-20024 is a Phase 4, multi-center, open-label safety study evaluating the potential effect of JATENZO on adrenal function in hypogonadal men treated with JATENZO for 12 months. conditions: Hypogonadism studyType: INTERVENTIONAL phases: PHASE4 allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 110 type: ESTIMATED name: Jatenzo measure: CST Test measure: Adrenal Insufficiency measure: Estrogen changes measure: Follicle Stimulating Hormone (FSH) changes. measure: Luteinizing hormone (LH) changes measure: Sperm analysis measure: Sperm analysis measure: Sperm analysis measure: Testis volume analysis sex: MALE minimumAge: 18 Years maximumAge: 65 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False